Elon Musk Explores Possible Tesla-SpaceX Merger Amid Growing AI Investments 
Dow Hits Record High as Healthcare and Consumer Stocks Lead Wall Street Rally 
South Korea Central Bank Holds Interest Rates Steady Amid Inflation Concerns 
Wall Street Climbs as Micron Leads Chip Stock Rally Amid Iran Peace Hopes 
Mega IPOs Like SpaceX and OpenAI Could Reshape S&P 500 and Nasdaq 100 Portfolios in 2026 
Meta AI Push Could Add $26 Billion in Revenue by 2027, Wolfe Research Says 
SpaceX IPO Hype Raises Questions as Many Major Stock Debuts Underperform Market 
Snowflake Stock Soars 30% After Q1 Earnings Beat and Major AWS AI Partnership 
U.S. Launches New Strikes on Iran as Trump Signals Peace Deal Uncertainty 
EU Antitrust Probe Could Lead to Massive Google Fine Under DMA Rules 
Yen Stays Near Intervention Zone as Iran Conflict Supports U.S. Dollar 
SpaceX Delays Starship V3 Launch Ahead of Potential Record IPO 
Gold Prices Slip as Stronger Dollar and Iran Peace Talk Uncertainty Weigh on Market 
NIO CEO Says China’s Auto Industry Has Passed Its Golden Era Amid Weak Car Sales 
Nikkei Hits Record High as AI Chip Stocks Power Japan Market Rally 
Toshifumi Suzuki, Founder of Seven-Eleven Japan, Dies at 93 
Celltrion and Mirae Asset were said to have agreed on buying the largest stake in the UK-headquartered antibody-drug conjugates developer, Iksuda Therapeutics. Based on the report, the deal between the companies is worth $47 million.
The stake acquisition deal
As per The Korea Economic Daily, with its huge investment, Celltrion Inc. is expecting to expand its cancer drug line. The biopharmaceutical company headquartered in Incheon, South Korea, wants to develop more treatments in addition to its Truxima, a blood cancer drug, and Herzuma for breast cancer.
It was said that Iksuda has four ADC-based drugs that are already in pre-clinical development, including B-cell lymphomas. Celltrion can make use of these once the deal is fully completed.
ADC is an advanced technology that was created to specifically target a cancer cell. In any case, Celltrion and Mirae Asset have paid half of the investment price to the British biotech firm, and the rest of the payment will be delivered once agreed development milestones are reached.
"This stake investment will create synergy with our antibody treatments and add next-generation anticancer drugs to our pipeline," a Celltrion official said.
The benefits from the investments for Iksuda
Celltrion and Mirae Asset’s investment in Iksuda Therapeutics will make them the largest stakeholder in the UK-based company. The funding coming from the Korean firms will go to the development and advancement of Iksuda’s lead ADC assets and other technologies.
It was mentioned that Iksuda’s lead pre-clinical drug is called IKS03, and it is said to be a “best-in-class” CD19-targeted ADC candidate for B-cell cancers. Celltrion and Mirae’s multi-million investment will be used for IKSO3 to progress from its first human phase 1 clinical trial.
“This is a transformational investment milestone for Iksuda, enabling us to focus on the progression of our industry-leading ADC programs and bring them to the clinic, whilst supporting our commercial growth,” Iksuda Therapeutics CEO, Dr.Dave Simpson, said in a press release. “The funding not only reflects the potential of our technologies but also the unmatched expertise of the Iksuda team. We are grateful for the support of this group of investors and delighted to welcome them to the team.
